Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript

Tom Riga: Yes. So it’s a great question. Thank you. I think as we look at this, the vast majority of the value for ONC201, we see in the U.S., and we are more than capable and ready to commercialize with a lean and efficient force. Secondly, I think as a reminder, we do have partners in Japan and China for ONC201, ONC206, by the way, is totally unencumbered. But in other geographies, whether it be Europe or South America, especially Europe, there are some challenges in commercializing there, and we don’t take that lightly. And they’re very well may be an alternate partner that could do it more efficiently. But we’ll evaluate that once we get the pivotal data we’ll look to maximize value either as a standalone doing it commercially or finding a partner that allows us to retain some of the economics for those geographies. But I think really, that decision will come down to what we see when we get that pivotal data.

Soumit Roy: Great. Thank you again for taking all the questions and congratulations on the progress.

Tom Riga: Thanks Soumit.

Operator: Since there are no further questions at this time. I’ll turn the call back over to Mike Andriole.

Mike Andriole: Thank you, everyone, for joining the call today, and we look forward to additional updates next quarter.